Unfortunately, most patients present with advanced or metastatic disease, when systemic chemotherapy is the only treatment option. carry mutations in EGFR, HER2, and MAPK pathway. In light of this emerging knowledge, clinical trials have become more biomarker-driven, which allows capturing of subsets of patients that are most likely to respond to certain therapies. Many new…
Category: Miscellaneous Opioids
Both authors contributed to the article and approved the submitted version
Both authors contributed to the article and approved the submitted version. Conflict of Interest PF has received funding from Insightec which has funded some of the clinical studies cited. the delivery of newly developed molecular therapies. Keywords: FUS, blood-brain barrier, Alzheimer’s disease, Parkinson’s disease, focused ultrasound (MRgFUS) In spite of major gains in the understanding…